Centre National De La Recherche Scientifique

College De France

Institut National De La Sante Et De La Recherche Medicale

Ecole Normale Superieure

Sorbonne Université

Other

Inserm (institut National De La Sante Et De La Recherche Medicale)

Institut National De La Sante Et De La Recherche Medicale (inserm)

Alain Prochiantz

Kenneth Lee Moya

Rajiv Joshi

Ariel Di Nardo

Bernadette Allinquant

Alain Joliot

Wolfgang Wurst

Marine Beurdeley

Takao Hensch

Michel Volovitch

Edmond Dupont

Gerard Chassaing

Jean-Maurice Mallet

Solange Lavielle

Julia Fuchs

François Xavier Blaudin De The

Hocine Rekaik

Damien Testa

Rodrigue Marquant

Olivia Massiani-Beaudoin

Karen Arnaud

Takao K Hensch

The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.

Ligand controling interaction between gags with their effector molecules and use thereof

The disclosure provides a method of delivering a polypeptide molecule to an Otx2 target cell, including contacting the target cell with a chimeric polypeptide having (i) a targeting peptide consisting of SEQ ID NO: 2 and (ii) the polypeptide molecule.

Methods of delivering a polypeptide molecule to Otx2 target cells using an Otx2 targeting peptide

The invention relates to the use of a homeoprotein of the bicoid family, in particular of the Otx family, for enhancing the survival of cultivated retinal ganglion neurones, and for preventing or treating ganglion neuron degeneration particularly occurring in glaucoma.

Methods of reducing excitotoxicity-induced retinal ganglionic neuron degeneration by an orthodenticle HOMOLOG2 (OTX2) homeoprotein

The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neurons.

Use of engrailed proteins for increasing dopamine synthesis by dopaminergic neurons

The invention relates to the use of a reverse-transcriptase inhibitor in the prevention or treatment of a degenerative disease.

Use of a reverse-transcriptase inhibitor in the prevention and treatment of degenerative diseases

The invention relates to the treatment of neurodegenerative diseases, in particular Alzheimer's disease, by inhibition of the synthesis of &#x3b2;APP or of the activity of the A&#x3b2; peptide in the choroid plexus.

Inhibition of the synthesis of beta-app or the activity of the A-&#x3b2; peptide in the choroid plexus

The present invention relates to the use of an Engrailed transcription factor for producing a medicament for anxiolytic purposes.

Use of the engrailed homeodomain protein as anxiolytic

The invention concerns peptide vectors, comprising a transduction domain, and a nuclear export sequence, for carrying a molecule of interest through an epithelium with tight junctions, such as the blood-brain barrier.

Carrier vectors through an epithelium with tight junctions

The invention concerns novel uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (APP); said peptides are in particular sequences including the membrane domain juxtaposed to the cytoplasmic domain of the amyloid protein precursor (APP) (one-letter code), selected in the group consisting of the sequences YKQYTSIHHGY(SEQ ID NO:2). YKKQYTSIHHGY(SEQ ID NO:3) and YKKKQYTSIHHGY(SEQ ID NO:4), wherein Yis nil or represents V, VV, VVE, VVEV or VVVED and Yrepresents an internalisation and addressing peptide, derived from the 3rd helix of homeodomains and structually related peptides. The invention also concerns the use of a peptide comprising the membrane domain juxtaposed to the cytoplasmic domain of the amyloid protein precursor (APP), for selecting and screening products capable of inhibiting apoptosis.

Applications of peptides derived from the cytoplasmic domain of amyloid precursor protein (APP)

The invention concerns novel uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (APP); said peptides are in particular sequences including the membrane domain juxtaposed to the cytoplasmic domain of the amyloid protein precursor (APP) (one-letter code), selected in the group consisting of the sequences YKQYTSIHHGY(SEQ ID NO:2). YKKQYTSIHHGY(SEQ ID NO:3) and YKKKQYTSIHHGY(SEQ ID NO:4), wherein Yis nil or represents V, VV, VVE, VVEV or VVVED and Yrepresents an internalisation and addressing peptide, derived from the 3helix of homeodomains and structurally related peptides. The invention also concerns the use of a peptide comprising the membrane domain juxtaposed to the cytoplasmic domain of the amyloid protein precursor (APP), for selecting and screening products capable of inhibiting apoptosis.

Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (APP)

Transcription factor responsive elements, target genes, and co-factors of a transcription factor, either individually or in combination, are identified by integrating into the genome of a eukaryotic cell a gene trap vector that includes a reporter gene, a polyadenylation site, and a selectable marker gene, selecting the cells in which the gene trap vector is successfully integrated and contacting those cells with the transcription factor, then identifying and cultivating those cells having a gene into which the gene trap vector has been integrated and in which the reporter gene activity has been altered by interaction between the transcription factor and a transcription factor responsive element of that gene, and identifying the transcription factor responsive element, target gene, or cofactor that interacts with the transcription factor.

Method for identification of target genes of transcription factors

Peptides which can be used as vectors for the intracellular addressing

The invention relates to a method for introducing a macromolecule comprising at least the helix 3 of a homeobox peptide into a living cell. In particular the macromolecule is active as a cell growth factor, in particular a neurotrope.

Growing community of inventors

Paris, France

Alain Prochiantz